Estamos no ar no ! Saiba mais

Neuropace

NPCE

Valor de mercado US$ 420 mi

12,24 USD

-0,54

4,23%

No fechamento Atualizado 16 de out. 16:00 EDT

Pré-mercado

Após o fechamento do mercado

12,24

0,00

0%

1 dia

-4,23%

5 dias

-2,24%

1 mês

-13,19%

3 meses

-25,68%

6 meses

-20,93%

No acumulado do ano

-19,31%

1 ano

15,04%

5 anos

-21,54%

10 anos

-50,96%

Sobre: NeuroPace Inc is a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of seizures. The company offers the RNS System, a brain-responsive neuromodulation system that continuously monitors and analyzes the brain's electrical activity and delivers personalized, real-time electrical pulses at the seizure source to prevent seizures. The RNS System includes the RNS neurostimulator, cortical strip leads, depth leads, a Patient Remote Monitor, and other implantable and non-implantable accessories used during implant procedures. The company also provides the Physician Tablet, Patient Data Management System, and the nSight Platform to facilitate ongoing patient monitoring and support clinicians in managing patient care.

Funcionários: 220

Saúde Dispositivos médicos

Notícias

Positivo

Neutro

Negativo

Sentimento 3 meses

Positivo 26,7%

Neutro 60%

Negativo 13,3%

Zacks Investment Research

Why Is NeuroPace (NPCE) Down 0.4% Since Last Earnings Report?

NeuroPace (NPCE) reported earnings 30 days ago. What's next for the stock?

Why Is NeuroPace (NPCE) Down 0.4% Since Last Earnings Report?

Zacks Investment Research

Here's Why You Should Retain NeuroPace Stock in Your Portfolio for Now

NPCE's RNS adoption, reimbursement gains, referral expansion and AI tools support growth, while IGE delays and higher spending pressure profitability.

Here's Why You Should Retain NeuroPace Stock in Your Portfolio for Now

NeuroPace to Participate in 2026 Cantor Global Healthcare Conference

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that its management team will participate in the upcoming 2026 Cantor Global Healthcare Conference. NeuroPace management will participate in a fireside chat discussion on Wednesday, September 9 at 10:55am EDT, and host one-on-one meetings with investors during the conference. The fireside chat will be accessible via a.

NeuroPace to Participate in 2026 Cantor Global Healthcare Conference

NeuroPace to Participate in Wells Fargo 21st Annual Healthcare Conference

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that its management team will participate in the upcoming Wells Fargo 21st Annual Healthcare Conference. NeuroPace management will participate in a fireside chat discussion on Tuesday, September 8 at 8:00am EDT, and host one-on-one meetings with investors during the conference. The fireside chat will be accessible via.

NeuroPace to Participate in Wells Fargo 21st Annual Healthcare Conference

Zacks Investment Research

NeuroPace Faces an IGE Delay: What the FDA Setback Means for Growth

NPCE's IGE expansion faces a regulatory delay, shifting focus to rising RNS adoption as the company works through the FDA review process.

NeuroPace Faces an IGE Delay: What the FDA Setback Means for Growth

Zacks Investment Research

Is NeuroPace a Buy as Growth Improves but Valuation Stays Elevated?

NPCE's stronger RNS adoption, narrowing losses and AI expansion support growth, but premium valuation, liquidity and regulatory risks warrant patience.

Is NeuroPace a Buy as Growth Improves but Valuation Stays Elevated?

Zacks Investment Research

NPCE Is Down 12.7% in 3 Months: Is the Pullback a Buying Opportunity?

NeuroPace's stronger RNS growth, raised 2026 guidance and AI expansion face a less certain IGE regulatory path after the FDA setback.

NPCE Is Down 12.7% in 3 Months: Is the Pullback a Buying Opportunity?

NeuroPace, Inc. (NPCE) Q2 2026 Earnings Call Transcript

NeuroPace, Inc. (NPCE) Q2 2026 Earnings Call Transcript

NeuroPace, Inc. (NPCE) Q2 2026 Earnings Call Transcript

Zacks Investment Research

NPCE Q2 Earnings Beat Estimates on RNS Growth, '26 Revenue View Up

NeuroPace's Q2 revenues rise 17.1% as RNS demand strengthens, while a narrower loss and higher 2026 outlook highlight continued momentum.

NPCE Q2 Earnings Beat Estimates on RNS Growth, '26 Revenue View Up

NeuroPace Q2 Earnings Call Highlights

NeuroPace NASDAQ: NPCE reported second-quarter revenue growth driven by continued adoption of its RNS System for adult focal epilepsy, while raising its full-year revenue and adjusted EBITDA outlook. The company also said it is pursuing additional discussions with the U.S. Food and Drug Administration regarding its application to expand the RNS System's indication into idiopathic generalized epilepsy, or IGE.

NeuroPace Q2 Earnings Call Highlights

Ver ranking de notícias

Gráficos de preços implementados com Lightweight Charts™